The initiative will focus particularly on patients with advanced organ failure and those whose immune systems contain antibodies that make conventional transplantation more difficult. These antibodies can recognize donor tissues as foreign and trigger rapid or severe rejection. In xenotransplantation, the biological distance between pigs and humans creates an even more complex immunological challenge. Researchers at Baylor will study how the human immune system identifies and attacks porcine tissue, while testing strategies intended to make a transplanted xenoliver more compatible with its recipient.

John Goss, chief of abdominal transplant in Baylor’s Michael E. DeBakey Department of Surgery, and William K. Decker, professor of pathology and immunology, will serve as co-directors of the new center. Their work will combine surgical expertise with research into immune regulation, tissue compatibility and transplant biology. The collaboration is designed not simply to examine whether a pig liver can function in a human body, but to understand the molecular and cellular mechanisms that determine whether the organ survives, adapts and performs its essential physiological roles.

A major component of the research will examine immunomodulation, or the deliberate adjustment of immune activity to promote tolerance. The investigators will explore the role of dendritic cells, specialized immune cells that process foreign proteins and help direct the adaptive immune response. Depending on the signals they receive, dendritic cells can activate aggressive immune reactions or contribute to a more tolerant state. Understanding how to influence these cells could help researchers reduce rejection without suppressing the recipient’s entire immune system, an approach that can leave transplant patients vulnerable to infections and cancer.

United Therapeutics is developing organs through several investigational platforms, including genetically edited pig organs intended for human transplantation. Its xenotransplantation program includes UKidney, UThymokidney and UHeart, all derived from pigs whose genomes have been modified to improve immunological acceptance and biological compatibility. Such edits may remove or alter pig molecules recognized by human antibodies, add human genes that help regulate blood clotting and inflammation, or reduce biological signals that provoke an immediate immune attack. The company’s partnership with Baylor extends this organ-manufacturing effort into the study of xenoliver transplantation.

The liver presents distinctive opportunities and obstacles for xenotransplantation. Unlike some organs, it performs a wide range of functions, including detoxifying blood, producing proteins, regulating metabolism and controlling aspects of immunity. A transplanted liver must therefore interact continuously with the recipient’s blood and immune system. Researchers must determine whether a genetically modified porcine liver can maintain these functions in a human physiological environment while avoiding complications such as antibody-mediated rejection, uncontrolled inflammation, abnormal coagulation or injury to the blood-vessel lining.

The need for alternative organs is substantial. Liver candidates are the second-largest group of people waiting for organ transplantation in the United States, with approximately 10,000 individuals currently on the national waiting list. The number of patients needing transplantation can exceed the supply of donated organs, and some candidates deteriorate rapidly while waiting. Others may be difficult to match with an available donor because of blood type, antibody profiles or other medical factors. Xenotransplantation could eventually provide organs on demand, potentially allowing physicians to intervene before irreversible organ failure develops.

Baylor leaders described the agreement as a convergence of the institution’s long history in transplantation and United Therapeutics’ efforts to manufacture transplantable organs. Baylor’s transplant program includes heart, lung, abdominal, liver and kidney transplantation, and the medical school has been involved in transplant research since the first heart transplant performed there in 1968. The new center will use this clinical background to connect laboratory findings with the practical requirements of surgery, organ preservation, patient selection and long-term post-transplant care.

The researchers emphasized that the objective is to make xenotransplantation a dependable medical option rather than to pursue only incremental improvements. The work will dissect both allogeneic immune responses, which occur between genetically different members of the same species, and xenogeneic responses, which arise between different species. By comparing these pathways, scientists hope to identify the barriers that are unique to pig-to-human transplantation and develop targeted methods to overcome them. Although significant scientific, regulatory and ethical questions remain, the Baylor-United Therapeutics collaboration could help determine whether xenolivers become a practical answer to the organ shortage.

Subject of Research: Xenoliver transplantation, immune tolerance and immunomodulation

Article Title: Baylor and United Therapeutics Launch Center to Advance Xenoliver Transplantation

Keywords: Xenotransplantation, xenoliver, liver transplantation, organ shortage, genetically modified pigs, immunomodulation, dendritic cells, transplant immunology, Baylor College of Medicine, United Therapeutics

The transplant utilized pig kidneys from alpha-Gal knockout pigs, genetically engineered to eliminate a key antigen responsible for triggering hyperacute rejection in xenotransplantation. Unlike prior highly modified grafts that incorporated multiple genetic alterations and aggressive immunosuppression regimens, this study employed kidneys with minimal genetic modification and clinically approved immunosuppressive drugs, notably without CD40 pathway blockade. These deliberate methodological choices aimed to emulate more realistic clinical conditions and assess the intrinsic capabilities of such modified organs.

Post-transplant, the pig kidneys supported hemodynamic stability and electrolyte balance, ultimately liberating the recipient from dialysis dependence. Such findings highlight the capacity of xenografts from gene-edited pigs to sustain essential renal functions in a human physiological environment, laying a foundation for future therapeutic applications beyond experimental models.

Initial histopathological analyses on postoperative day 10 revealed unique immunological responses within the transplanted graft. There was prominent glomerular deposition of IgM and IgA antibodies alongside activation of early complement components and evidence of mesangiolysis—a pattern not typical of traditional allotransplant rejection. Remarkably, these changes occurred in the context of stable renal function without proteinuria, suggesting a distinct immunological milieu characterizing pig-to-human xenotransplantation.

However, by postoperative day 33, serum creatinine levels acutely elevated, signaling impending graft dysfunction. This biochemical indicator coincided with clinical and histological hallmarks of antibody-mediated rejection, including an increase in donor-specific IgG antibodies. These immunological developments prompted the clinical team to initiate therapeutic interventions targeting the antibody-mediated alloimmune response.

A combination therapy involving plasma exchange, C3/C3b complement inhibition, and rabbit anti-thymocyte globulin (rATG) proved efficacious, completely reversing the rejection episode. This multimodal approach underscores the complexity of managing xenogeneic immune responses and the potential necessity of integrating complement inhibition and lymphocyte-depleting strategies to maintain graft viability.

In-depth immunologic monitoring revealed expansion and activation of pre-existing donor-reactive T cell clones circulating in the recipient. These T cells progressively acquired an effector phenotype with transcriptional profiles characteristic of immune activation. At the time of rejection, these alloreactive clones were detected within the graft itself prior to the administration of rATG, implicating them as central mediators in the immunopathogenesis of xenograft failure.

This study is the first to provide comprehensive long-term monitoring encompassing physiological performance, immunologic dynamics, and infectious risk in a pig-to-human kidney transplant setting. The findings reveal that, despite significant immunosuppressive efforts, pre-existing xenoreactive T cells combined with antibodies targeting currently unidentified epitopes remain formidable barriers to sustained xenograft survival.

The transplantation’s success in providing life-supporting renal function for over two months substantiates the promise of minimally gene-edited pig organs. This proof-of-concept paves the way for refinement of genetic engineering techniques and immunomodulatory protocols to achieve durable graft acceptance without the extensive alterations previously deemed necessary.

With escalating global demand for donor kidneys and the persistent organ shortage crisis, xenotransplantation from genetically engineered pigs offers a tangible solution. The insights gleaned from this human cadaveric model facilitate the translation of findings into clinical trials and eventual therapeutic reality, fostering hope for thousands on transplant waitlists.

The implications of this research extend beyond nephrology, potentially informing xenotransplant strategies for other organ systems plagued by donor scarcity. As scientists decode the intricate interplay between human immune defenses and porcine graft antigens, novel targets for intervention and improved graft designs will emerge.

While ethical, regulatory, and infectious safety considerations accompany this promising frontier, the demonstrated feasibility of pig-to-human kidney transplantation propels the field toward tangible clinical application. Future efforts will focus on mitigating immune rejection, optimizing gene editing, and ensuring long-term graft function—goals essential for xenotransplantation to become a mainstream therapeutic option.

The publication of these findings in a prestigious scientific journal underscores the transformative potential of xenotransplantation to revolutionize organ transplantation. It heralds a new era where interspecies organ sharing may effectively address the unmet demands of patients with irreversible organ failure, reshaping transplantation medicine in profound ways.

Subject of Research:

Article Title:

Article References:
Montgomery, R.A., Stern, J.M., Fathi, F. et al. Physiology and immunology of pig-to-human decedent kidney xenotransplant. Nature (2025). https://doi.org/10.1038/s41586-025-09847-6

Image Credits: AI Generated

The motivation behind this pioneering research stems from the dire need for functional human organs to treat renal failure. Traditional organ donation remains vastly inadequate, with thousands of patients awaiting transplants each year. By creating human kidney organoids, researchers hope to pave the way for a scalable solution that could significantly alleviate the burden on the transplant waiting list while improving patient outcomes.

The groundwork for the study was laid through meticulous research into stem cell biology and tissue engineering. Human kidney organoids are formed from pluripotent stem cells, which can develop into various cell types. This remarkable ability allows scientists to replicate kidney structures and functions in vitro, closely mirroring those of real human organs. In their study, the authors detail the step-by-step process of developing these organoids, ensuring consistency and functionality.

One of the key highlights of Garreta et al.’s work is the integration of ex vivo machine perfusion—an innovative technique that allows for the continuous supply of nutrients and oxygen to the organoids. This method significantly enhances the viability and function of the organoids when transplanted into porcine kidneys, which serve as a preclinical model. The results demonstrate that the organoids not only survive but thrive in this environment, exhibiting characteristics akin to those of natural kidneys.

Furthermore, the researchers explored how different perfusion parameters impact the growth and maturation of the organoids. By adjusting flow rates and perfusion pressures, they were able to optimize conditions that promote kidney-specific functions such as filtration and hormone synthesis. Such refinements are critical for ensuring that the transplanted organoids can adequately support bodily functions post-transplantation.

The study provided compelling evidence of the organoids’ ability to respond to physiological signals similar to actual human kidneys. This responsiveness is pivotal, as it suggests that these bioengineered organs could integrate seamlessly into host systems, potentially leading to functional kidney replacements that minimize rejection chances.

Additionally, ethical considerations surrounding organ transplantation were addressed. The ability to produce human organoids from stem cells poses a transformative potential for reducing reliance on human donors and addresses moral concerns associated with organ harvesting. As the development of human kidney organoids progresses, it also opens doors for personalized medicine, where patients can receive organoids tailored to their genetic makeup, thereby enhancing compatibility and efficacy.

The implications of this research extend far beyond kidney transplants. The methodologies addressed in this study could be adapted for generating organoids for other organs, thus laying the groundwork for an organ-specific transplantation revolution. As scientists delve deeper into the complexities of organoid production, the dream of growing fully functional human organs within a laboratory setting inches closer to reality.

Moreover, the combination of tissue engineering and bioprinting technologies holds promise for the future of organ fabrication. As methods for 3D printing biocompatible scaffolds develop, researchers can envision creating complex, multidimensional organ structures that encompass intricate vasculature and cellular diversity, mirroring the functionality of native organs.

In conclusion, Garreta et al. present a paradigm shift in the field of regenerative medicine with their systematic approach to human kidney organoid production. Their work not only addresses the urgent need for organ transplant solutions but also sets the stage for future advancements in organ engineering. By harnessing the potential of stem cells and machine perfusion, this research contributes meaningfully to the ongoing narrative of scientific progress in overcoming the limitations of human health.

As this revolutionary study captures the interest of the scientific community, it is essential for continued funding and research to explore the myriad possibilities that lie ahead. A future where bioengineered organs can effectively replace damaged ones may soon be within reach, thanks to these pioneering efforts in kidney organoid transplantation.

Subject of Research: Systematic production of human kidney organoids for transplantation.

Article Title: Systematic production of human kidney organoids for transplantation in porcine kidneys during ex vivo machine perfusion.

Article References:

Garreta, E., Moya-Rull, D., Centeno, A. et al. Systematic production of human kidney organoids for transplantation in porcine kidneys during ex vivo machine perfusion.
Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01542-1

Image Credits: AI Generated

DOI: 10.1038/s41551-025-01542-1

Keywords: Kidney organoids, transplantation, ex vivo machine perfusion, stem cells, regenerative medicine, organ engineering.